Spectrophotometric determination of the cardioprotective drug GP531 in human plasma.
A simple spectrophotometric assay has been developed for determining concentrations of the new cardioprotective agent, GP531, in human plasma. The method is adapted from the Bratton-Marshall assay (BMA) for the detection of primary aromatic amines. The assay can be used to measure plasma concentrations of the drug during i.v. infusion administration to patients. The limit of quantitation of the assay is 1 microgram/ml using a 0.8 ml sample ultrafiltrate of plasma. The colorimetric assay correlates well with a previously described high performance liquid chromatographic (HPLC) procedure.
Department of Pharmacokinetics and Drug Metabolism, Gensia, Inc., San Diego, CA 92121, USA.
H M
HM
Grettenberger
J M
JM
Fujitaki
L S
LS
Chen
R
R
Dixon
D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000097:blood; D002317:Cardiovascular Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D003124:Colorimetry / Q000379:methods; D003853:Deoxyribonucleosides / Q000097:blood*; D006801:Humans; D013053:Spectrophotometry / Q000379:methods
D002317:Cardiovascular Agents; D003853:Deoxyribonucleosides; C103214:GP 531; D000620:Aminoimidazole Carboxamide